151982-51-3Relevant articles and documents
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability
Engers, Darren W.,Bollinger, Sean R.,Engers, Julie L.,Panarese, Joseph D.,Breiner, Megan M.,Gregro, Alison,Blobaum, Anna L.,Bronson, Joanne J.,Wu, Yong-Jin,Macor, John E.,Rodriguez, Alice L.,Zamorano, Rocio,Conn, P. Jeffrey,Lindsley, Craig W.,Niswender, Colleen M.,Hopkins, Corey R.
, p. 2641 - 2646 (2018)
Previous reports from our laboratory disclosed the structure and activity of a novel 1H-pyrazolo[4,3-b]pyridine-3-amine scaffold (VU8506) which showed excellent potency, selectivity and in vivo efficacy in preclinical rodent models of Parkinson's disease.
Method for synthesizing high-purity tert-butyl 2-fluoro-4-bromobenzoate
-
Paragraph 0027, (2021/08/19)
The invention discloses a method for synthesizing high-purity tert-butyl 2-fluoro-4-bromobenzoate, which comprises the following steps: synthesizing a compound 2-fluorine-4-bromobenzoyl chloride from 2-fluorine-4-bromobenzoic acid, then synthesizing the t
CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND
-
Paragraph 0177-0178, (2021/09/03)
Provided herein is a crystalline hydrate of the compound of formula 1: Also provides herein are pharmaceutical compositions comprising such crystalline hydrate, methods of using such crystalline hydrate to treat respiratory diseases, and processes useful